- Market Realist•13 days ago
On July 1, 2016, Alnylam Pharmaceuticals (ALNY) published positive preliminary results from its Phase 2 open label extension (or OLE) study.
Alnylam Pharmaceuticals, Inc.NasdaqGS
After hours: 66.810.00 (0.00%) as of 5:18 PM EDT
|Bid||63.50 x 600|
|Ask||68.60 x 100|
|52wk Range||49.96 - 132.00|
|Day's Range||65.66 - 68.87|
|Avg Vol (3m)||980,895|
As of 4:00 PM EDT. Market closed.